Skip to content
NEWS
EVENTS
Primary-Full-Color
  • About KCNQ2
    • What are KCNQ2-related disorders
    • Q2 Quick Notes
    • Recruiting Research Studies
    • KCNQ2 ICD Codes
    • FAQ
    • In Loving Memory
  • Caregivers
    • Newly Diagnosed
    • KCNQ2 Family Network
    • Research Where To Begin
    • Resources
    • Bi-Annual Summit
    • News & Blog
    • Patient Assistance Grant
    • Find A Doctor
    • Our Stories
  • Providers
    • Clinical Trials
    • Research Review
    • Doctor Registration
  • Research
    • For Researchers
    • Research Resources
    • Grant Program
    • For Caregivers
    • Recruiting Research Studies
    • Biorepository
  • Get Involved
    • Fundraise
    • Ways to Give
    • KCNQ2 Channel Changers
    • Volunteer
    • Awareness Week – March
    • Share Your Story
  • About Us
    • Our Role
    • Our Team
    • Scientific Advisory Board
    • Global Reach
    • Finances
    • Contact Us
Donate

Press Releases

News and Media / Press Releases

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference

May 24, 2019
Read More

Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update

March 6, 2019
Read More

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

February 26, 2019
Read More

Xenon Pharmaceuticals Outlines 2019 Key Milestones

January 6, 2019
Read More

Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

November 6, 2018
Read More

Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy

September 6, 2018
Read More

NINDS Launches New Epilepsy Center Without Walls

August 1, 2018
Read More

Pairnomix And KCNQ2 Cure Alliance Report Findings From Comprehensive Drug Screening In A Cellular Model Of KCNQ2 Epileptic Encephalopathy

December 4, 2017
Read More

Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial

October 17, 2017
Read More

Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy

April 26, 2017
Read More
  • 1
  • 2
  • Next »

KCNQ2 Cure Alliance

EIN# 47-1810644

A 501(c)(3) nonprofit organization

About Us

Research

Family Support

Events

Get Involved

Donate

Sign Up for our KCA Newsletter

Candid Transparency Seal Charity Navigator 4-star rating
info@kcnq2cure.org

info@kcnq2cure.org

3700 Quebec Street Unit 100-118 Denver, CO 80207

Privacy Policy
Terms and Condtions

©2026 KCNQ2 Cure Alliance. All Rights Reserved.

Scotty Sims

Scotty Sims, MEd

Executive Director

Before her career as a crisis therapist, where she provided support and assessment to children and adults with severe and persistent mental illness, Scotty served as a forensic interviewer, trained to work with children who were victims of sexual abuse for multidisciplinary teams and the court system. Drawn to helping others, she found purpose in roles that allowed her to support people facing significant challenges. After her daughter was born and diagnosed with KCNQ2-DEE, Scotty identified a lack of support systems and resources for caregivers of those with KCNQ2-related disorders. This led her to create the international KCNQ2 caregiver support group. Through this group, she met other families who shared a vision for support and advocacy, leading to the first KCNQ2 Summit in Colorado, which brought together families, clinicians, researchers, and industry stakeholders. Recognizing the need for ongoing resources and research funding, Scotty co-founded the KCNQ2 Cure Alliance. Scotty lives in Colorado with her husband and two children.

Newsletter sign up

About You

Your Name(Required)
Your Email Address(Required)
This field is hidden when viewing the form
Your Address
This field is hidden when viewing the form